Literature DB >> 12667112

Pharmacotherapy of cancer-related episodic pain.

Giovambattista Zeppetella1, Maria D C Ribeiro.   

Abstract

Episodic pain is a transient increase in pain intensity over background pain. Episodic pain occurs commonly in cancer patients; it is a heterogeneous phenomenon that is incapacitating, debilitating and can have a significant impact on quality of life. Episodic pain can be difficult to manage; it is often unpredictable, typically of fast onset, of short duration and feels similar to background pain except that it may be more severe. The successful management of episodic pain can only be achieved following a thorough assessment. The subsequent management usually involves both pharmacological and non-pharmacological strategies integrated into the overall care and appropriate for the stage of the patient's disease. Pharmacological management includes the implementation of primary therapies (e.g., chemotherapy for the underlying aetiology of the pain, optimising the scheduled medication (e.g., analgesics and adjuvant analgesics) and specific pharmacological interventions for the episodic pain (e.g., rescue medication).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667112     DOI: 10.1517/14656566.4.4.493

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

1.  [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].

Authors:  Vicente Valentín Maganto; Carlos Camps Herrero; Joan Carulla Torrent; Javier Cassinello Espinosa; Javier Dorta Delgado; Carlos Jara Sánchez; José Andrés Moreno Nogueira
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 2.  Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Authors:  Frank Elsner; Giovambattista Zeppetella; Josep Porta-Sales; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.

Authors:  Paul Sloan; Neal Slatkin; Harry Ahdieh
Journal:  Support Care Cancer       Date:  2004-11-09       Impact factor: 3.603

Review 4.  Breakthrough pain in elderly patients with cancer: treatment options.

Authors:  Sophie Pautex; Nicole Vogt-Ferrier; Gilbert B Zulian
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

5.  Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.

Authors:  Albert Tuca Rodríguez; Miguel Núñez Viejo; Pablo Maradey; Jaume Canal-Sotelo; Plácido Guardia Mancilla; Sonia Gutiérrez Rivero; Inmaculada Raja Casillas; María Herrera Abián; Cristina López Bermudo
Journal:  Support Care Cancer       Date:  2021-02-03       Impact factor: 3.359

6.  Back to the future, current trends in breakthrough pain treatments.

Authors:  Max Watson
Journal:  Indian J Palliat Care       Date:  2011-01

Review 7.  Assessment and treatment of breakthrough cancer pain: from theory to clinical practice.

Authors:  Renato Vellucci; Rocco Domenico Mediati; Silvia Gasperoni; Massimo Mammucari; Franco Marinangeli; Patrizia Romualdi
Journal:  J Pain Res       Date:  2017-09-12       Impact factor: 3.133

8.  PainVision® Apparatus for Assessment of Efficacy of Pulsed Radiofrequency Combined with Pharmacological Therapy in the Treatment of Postherpetic Neuralgia and Correlations with Measurements.

Authors:  Dong Wang; Kai Zhang; ShaoLong Han; LingZhi Yu
Journal:  Biomed Res Int       Date:  2017-03-05       Impact factor: 3.411

9.  Breakthrough Cancer Pain Is Associated with Spinal Gap Junction Activation via Regulation of Connexin 43 in a Mouse Model.

Authors:  Xin Li; Siqing Jiang; Hui Yang; Qian Liao; Shousong Cao; Xuebin Yan; Dong Huang
Journal:  Front Cell Neurosci       Date:  2017-07-17       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.